Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma | Haematologica
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Management of CLL in 2021 and Beyond - YouTube
Ibrutinib's Cardiotoxicity Comes Into Focus | MedPage Today
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on - Molica - 2020 - Hematological Oncology - Wiley Online Library
CHRONIC LYMPHOCYTIC LEUKEMIA
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL | Clinical Hematology International
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy - Oncology Nurse Advisor
Cancers | Free Full-Text | Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib (PCI-32765) | Btk Inhibitor | MedChemExpress
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
British Journal of Haematology | Wiley Online Library
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era | American Society of Clinical Oncology Educational Book
Studies on ibrutinib for newly diagnosed chronic lymphocytic leukemia... | Download Scientific Diagram
ALLIANCE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
